Akero Therapeutics

Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akero's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as three ongoing Phase 3 clinical trials in patients with pre-cirrhotic MASH or compensated cirrhosis due to MASH: SYNCHRONY Histology, SYNCHRONY Real-World, and SYNCHRONY Outcomes. The SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero is headquartered in South San Francisco.

Special Advisory:

Job applicants should be aware of online recruitment scams, including fraudulent interviews and fake job offers. Akero does not conduct interviews through text messages or messaging apps, will never request money from applicants, and communicates only via emails ending with "@akerotx.com." Please verify that any communication claiming to be from Akero comes from an official company email address. If you receive any suspicious messages, submit a report to the Federal Trade Commission.